PDB18 COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
| Autor: | Pawaskar, MD, Anderson, J, Zagar, AJ |
|---|---|
| Zdroj: | In Value in Health 2009 12(7):A404-A404 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect